Drug Discovery World features Dave Cole, Head of Research at Accession Therapeutics, discussing how oncolytic immunotherapy is being re‑engineered to overcome limitations in systemic delivery and immune engagement.

Proceeds will enable generation of full clinical data from ongoing Phase 1 study of TROCEPT-01 (ATTR-01), its lead programme in advanced solid tumours, and progression of TROCEPT-02 (ATTR-02) into the clinic. Oxford, UK, 4 December 2025 – Accession Therapeutics Limited, a clinical-stage biopharmaceutical company developing next generation cancer immunotherapies announces it has raised £30.5 million ($40 million USD) from its existing investors.

Accession Therapeutics Limited, a biopharmaceutical company developing next generation cancer immunotherapies, today announced it has dosed the first patient in its Phase I clinical trial evaluating TROCEPT-01 (ATTR-01), the company’s lead drug candidate from its proprietary TROCEPT platform technology.

At the ESMO Congress 2025, taking place between 17-21 October, Accession Therapeutics are sharing details of our ATTEST study, a first-in-human Phase 1 trial of ATTR-01 (TROCEPT-01) in patients with selected epithelial tumours.

Accession Therapeutics is pleased to announce that five abstracts showcasing the company’s TROCEPT cancer immunotherapy platform have been accepted for presentation at three leading international oncology conferences in 2025.

Accession Therapeutics obtains approval for first TROCEPT cancer clinical trial in UK